Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -19.08% is 81% above its 5-year average of -100.79%, near the high end of its 5-year range (-475.00%–-11.80%).
As of the fiscal period ended Wednesday, December 31, 2025. 33.05% above its 12-month average of -28.50%.
Annual fiscal-year return on equity; no daily interpolation. Historical series through 2025-12-31.
RETURN ON EQUITY (ROE)
-19.08%
RETURN ON EQUITY (ROE) AVG TTM
-28.50%
RETURN ON EQUITY (ROE) AVG 3Y
-28.27%
RETURN ON EQUITY (ROE) AVG 5Y
-100.79%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+33.05%
CURRENT VS 3Y AVG
+32.51%
CURRENT VS 5Y AVG
+81.07%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 753 covered companies
CURRENT VS SECTOR MEDIAN
+54.58%
vs the sector median at left
Pulsenmore Ltd. Ordinary Shares
Market Cap
$14.05M
Return on Equity (ROE)
-19.08%
TTM Avg
-28.50%
3Y Avg
-28.27%
5Y Avg
-100.79%
Market Cap
$13.86M
Return on Equity (ROE)
-372.67%
TTM Avg
-433.17%
3Y Avg
-292.89%
5Y Avg
-208.82%
Market Cap
$13.75M
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$14.46M
Return on Equity (ROE)
-186.95%
TTM Avg
1198.98%
3Y Avg
241.18%
5Y Avg
112.17%
Market Cap
$14.73M
Return on Equity (ROE)
N/A
TTM Avg
54.00%
3Y Avg
301.36%
5Y Avg
162.15%
Market Cap
$13.33M
Return on Equity (ROE)
-101.66%
TTM Avg
-140.38%
3Y Avg
-131.64%
5Y Avg
-101.94%
Market Cap
$13.30M
Return on Equity (ROE)
-39.76%
TTM Avg
-59.76%
3Y Avg
-51.18%
5Y Avg
-40.48%
Market Cap
$13.20M
Return on Equity (ROE)
-69.47%
TTM Avg
-55.64%
3Y Avg
-44.95%
5Y Avg
-41.56%
Market Cap
$14.94M
Return on Equity (ROE)
-42.72%
TTM Avg
-65.53%
3Y Avg
-58.02%
5Y Avg
-43.63%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Pulsenmore Ltd. Ordinary Shares (PLSM) | $14.05M | -19.08% | -28.50% | -28.27% | -100.79% |
| Sintx Technologies, Inc. (SINT)vs › | $13.86M | -372.67% | -433.17% | -292.89% | -208.82% |
| Obsidian Therapeutics Inc. (OBX)vs › | $13.75M | N/A | N/A | N/A | N/A |
| Vyome Holdings, Inc. (HIND)vs › | $14.46M | -186.95% | 1198.98% | 241.18% | 112.17% |
| Karyopharm Therapeutics Inc. (KPTI)vs › | $14.73M | N/A | 54.00% | 301.36% | 162.15% |
| IN8bio, Inc. (INAB)vs › | $13.33M | -101.66% | -140.38% | -131.64% | -101.94% |
| Optimi Health Corp. (OPTH)vs › | $13.30M | -39.76% | -59.76% | -51.18% | -40.48% |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $13.20M | -69.47% | -55.64% | -44.95% | -41.56% |
| Pasithea Therapeutics Corp. (KTTA)vs › | $14.94M | -42.72% | -65.53% | -58.02% | -43.63% |
| Passage Bio, Inc. (PASG)vs › | $13.11M | -810.41% | -174.22% | -126.94% | -100.46% |
ROE
-19.1%
ROA
-15.6%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | -19.08% |
| 2024-12-31 | -37.92% |
| 2023-12-31 | -44.29% |
| 2022-12-31 | -11.80% |
| 2021-12-31 | -16.67% |
| 2020-12-31 | -475.00% |
| 2019-12-31 | -117.29% |
